Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 5, 2011, Pages 492-494

  Launay Vacher, Vincent ^a   Ayllon, Jorge ^a   Janus, Nicolas ^a   Medioni, Jacques ^a   Deray, Gilbert ^a   Isnard Bagnis, Corinne ^a   Oudard, Stéphane ^a  

^a HÔpital Pitié Salpêtrière ^*  (France)

Author keywords

Antiangiogenic agents; Hypertension; Renal cancer; Renal function; Sorafenib; Sunitinib

Indexed keywords

BEVACIZUMAB; CREATININE; SORAFENIB; SUNITINIB;

ADULT; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CREATININE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; ONCOLOGY WARD; PRIORITY JOURNAL; RENOVASCULAR DISEASE; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; UNINEPHRECTOMY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; NEPHRECTOMY; PROGNOSIS; PYRIDINES; PYRROLES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 80052917736     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.07.023     Document Type: Article

References (8)

1. Oudard S., George D., Medioni J., et al. Treatment options in renal cell carcinoma: Past, present and future. Ann Oncol 2007, 18(Suppl 10):x25-x31.
2. Bhojani N., Jeldres C., Patard J.J., et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008, 53(5):917-930.
3. Launay-Vacher V., Deray G. Hypertension and proteinuria: A class-effect of antiangiogenic therapies. Anti-Cancer Drugs 2009, 20(1):81-82.
4. Levey A.S., Bosch J.P., Lewis J.B., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
5. Levey A.S., Eckardt K.U., Tsukamoto Y., et al. Definition and classification of chronic kidney disease: A position statement from kidney disease: Improving global outcomes (KDIGO). Kidney Int 2005, 67:2089-2100.
6. Launay-Vacher V., Oudard S., Janus N., et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: The renal insufficiency and anticancer medications (IRMA) study. Cancer 2007, 110:1376-1384.
7. Hemmelgarn B.R., Zhang J., Manns B.J., et al. Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int 2006, 69:2155-2161.
8. Chu T.F., Rupnick M.A., Kerkela R., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007, 370:2011-2019.